MC
MYGN icon

Moors & Cabot’s Myriad Genetics MYGN Stock Holding History

Moors & Cabot’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,350
Closed -$454K – 584
2018
Q1 		$454K Sell
15,350
-5,325
-26% -$180K 0.06% 349
2017
Q4 		$707K Hold
20,675
– – 0.09% 251
2017
Q3 		$744K Sell
20,675
-800
-4% -$22.8K 0.11% 224
2017
Q2 		$557K Buy
21,475
+5,375
+33% +$114K 0.09% 266
2017
Q1 		$315K Buy
+16,100
New +$285K 0.05% 373

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Moors & Cabot's MYGN Position: Q2 2018 in Review

Moors & Cabot sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 15,350 shares — an estimated $454K sold.

Moors & Cabot first reported a position in MYGN in Q1 2017 and held it in 5 quarters. The position peaked at $744K in Q3 2017. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • Moors & Cabot reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • Moors & Cabot sold 15,350 Myriad Genetics shares in Q2 2018, an estimated $454K.
  • Moors & Cabot first reported a position in Myriad Genetics in Q1 2017 and held it in 5 quarters.
  • Moors & Cabot's Myriad Genetics position peaked at $744K in Q3 2017.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Moors & Cabot's 13F filing for Q2 2018, filed 14 Aug 2018.